Contributors |
|
xiii | |
Editor Biography |
|
xv | |
Foreword |
|
xix | |
Preface |
|
xxi | |
|
1 Discovery and development of anti-inflammatory agents from natural products: an overview |
|
|
1 | (6) |
|
|
|
1 | (1) |
|
|
2 | (1) |
|
|
2 | (1) |
|
|
3 | (1) |
|
|
3 | (1) |
|
|
4 | (1) |
|
|
4 | (1) |
|
|
4 | (1) |
|
|
5 | (1) |
|
|
5 | (1) |
|
|
5 | (1) |
|
|
6 | (1) |
|
2 Curcumin: current evidence of its therapeutic potential as a lead candidate for anti-inflammatory drugs---an overview |
|
|
7 | (25) |
|
|
|
M. Pilar Gomez-Serranillos |
|
|
1 Introduction: general features and ethnopharmacological relevance |
|
|
7 | (3) |
|
2 Isolation, chemical biosynthesis, and characterization of curcumin |
|
|
10 | (3) |
|
3 Pharmacokinetics of curcumin |
|
|
13 | (3) |
|
4 Pharmacodynamics in inflammatory processes |
|
|
16 | (2) |
|
5 Semisynthesis of novel molecules from curcumin |
|
|
18 | (4) |
|
6 Preclinical studies: in vitro and animal research on the anti-inflammatory properties of curcumin and its derivatives |
|
|
22 | (10) |
|
6.1 Edema and global inflammation |
|
|
22 | (5) |
|
|
27 | (1) |
|
6.3 Gastrointestinal diseases |
|
|
27 | (1) |
|
|
28 | (1) |
|
6.5 Allergy and bronchial asthma |
|
|
29 | (1) |
|
|
30 | (1) |
|
|
31 | (1) |
|
6.8 Neurodegenerative diseases and cancer |
|
|
31 | (1) |
|
7 Clinical evidence of curcumin's anti-inflammatory benefits |
|
|
32 | (29) |
|
|
38 | (1) |
|
7.2 Inflammatory diseases of gastrointestinal tract |
|
|
39 | (1) |
|
|
40 | (1) |
|
7.4 Allergy and inflammatory diseases of respiratory tract |
|
|
41 | (1) |
|
|
42 | (1) |
|
|
43 | (1) |
|
7.7 Neurodegenerative diseases and cancer |
|
|
44 | (2) |
|
|
46 | (1) |
|
8 Curcumin as an anti-inflammatory drug: the reality and limitations |
|
|
47 | (1) |
|
|
48 | (1) |
|
|
49 | (2) |
|
|
51 | (10) |
|
3 Anti-inflammatory efficacy of some potentially bioactive natural products against rheumatoid arthritis |
|
|
61 | (40) |
|
|
|
|
|
|
|
61 | (1) |
|
2 Etiology of disease progression |
|
|
62 | (3) |
|
2.1 Genetic susceptibilities |
|
|
62 | (1) |
|
2.2 Autoimmunity and role of proinflammatory cytokines |
|
|
63 | (2) |
|
3 Current pharmacological treatments of rheumatoid arthritis and their drawbacks |
|
|
65 | (5) |
|
3.1 Nonsteroidal anti-inflammatory drugs |
|
|
65 | (1) |
|
|
66 | (1) |
|
3.3 Disease-modifying antirheumatic drugs |
|
|
66 | (2) |
|
|
68 | (2) |
|
4 Protective role of naturally occurring anti-inflammatory compounds |
|
|
70 | (15) |
|
|
70 | (13) |
|
|
83 | (1) |
|
|
84 | (1) |
|
5 Concluding remarks: challenges and future prospects |
|
|
85 | (3) |
|
|
88 | (1) |
|
|
89 | (12) |
|
4 Natural anti-inflammatory agents for the management of osteoarthritis |
|
|
101 | (40) |
|
|
|
|
|
|
101 | (2) |
|
2 Current treatments and their disadvantages |
|
|
103 | (1) |
|
2.1 Nonpharmacological therapy |
|
|
103 | (1) |
|
2.2 Pharmacological therapy |
|
|
103 | (1) |
|
3 Significance of natural products in the management of osteoarthritis |
|
|
104 | (1) |
|
4 Natural anti-inflammatory agents for management of osteoarthritis |
|
|
105 | (19) |
|
|
105 | (2) |
|
4.2 Harpagophytum procumbens |
|
|
107 | (4) |
|
|
111 | (6) |
|
|
117 | (4) |
|
|
121 | (3) |
|
|
124 | (1) |
|
|
124 | (4) |
|
|
128 | (1) |
|
|
128 | (1) |
|
|
128 | (13) |
|
5 Portrait of the synthesis of some potent anti-inflammatory natural products |
|
|
141 | (44) |
|
|
|
|
|
141 | (1) |
|
2 Total synthetic approaches for some anti-inflammatory natural products |
|
|
142 | (33) |
|
|
142 | (1) |
|
2.2 C-7 epimer of parthenolide |
|
|
143 | (2) |
|
2.3 1,8-Cineole and 1,4-cineole |
|
|
145 | (2) |
|
|
147 | (2) |
|
|
149 | (4) |
|
|
153 | (4) |
|
|
157 | (3) |
|
|
160 | (3) |
|
|
163 | (3) |
|
|
166 | (4) |
|
|
170 | (5) |
|
|
175 | (2) |
|
|
177 | (1) |
|
|
178 | (5) |
|
|
183 | (2) |
|
6 Recent developments in the anti-inflammatory potential of sesquiterpene lactones and their semisynthetic analogs |
|
|
185 | (22) |
|
|
|
185 | (2) |
|
2 Anti-inflammatory activity of sesquiterpene lactones |
|
|
187 | (12) |
|
|
187 | (3) |
|
|
190 | (2) |
|
|
192 | (1) |
|
2.4 Miscellaneous guaianolides |
|
|
192 | (1) |
|
2.5 Miscellaneous germacranolides |
|
|
193 | (2) |
|
|
195 | (1) |
|
|
195 | (1) |
|
|
196 | (1) |
|
2.9 Miscellaneous sesquiterpene lactones |
|
|
197 | (2) |
|
3 Structure---activity relationships (SAR) of sesquiterpenes lactones |
|
|
199 | (1) |
|
|
200 | (1) |
|
|
200 | (1) |
|
|
200 | (1) |
|
|
201 | (6) |
|
7 Hesperetin and naringenin: protective effects against metabolic syndrome---associated inflammation |
|
|
207 | (34) |
|
|
|
Paula de Paula Menezes Barbosa |
|
|
Isadora Ferreira da Silva |
|
|
Amanda Rejane Alves de Avila |
|
|
|
207 | (3) |
|
1.1 Obesity and metabolic syndrome |
|
|
207 | (1) |
|
1.2 Inflammatory pathways in metabolic syndrome |
|
|
208 | (1) |
|
1.3 Drugs effects in metabolic syndrome---associated inflammation |
|
|
209 | (1) |
|
2 Hesperetin and naringenin: effects on metabolic syndrome---associated inflammation |
|
|
210 | (4) |
|
|
211 | (1) |
|
|
212 | (2) |
|
3 Flavanone chemistry, structure---activity relation, and natural sources |
|
|
214 | (5) |
|
|
214 | (1) |
|
3.2 Structure---activity relations |
|
|
215 | (1) |
|
3.3 Natural sources of naringenin and hesperetin |
|
|
216 | (3) |
|
4 Fermentative and enzymatic biotransformation for hesperetin and naringenin |
|
|
219 | (6) |
|
4.1 Enzymatic biotransformation |
|
|
219 | (5) |
|
4.2 Microbial biotransformation |
|
|
224 | (1) |
|
5 Flavanone purification and identification |
|
|
225 | (5) |
|
|
225 | (3) |
|
5.2 Flavanone purification |
|
|
228 | (1) |
|
5.3 Flavanone identification |
|
|
229 | (1) |
|
|
230 | (1) |
|
|
231 | (1) |
|
|
232 | (9) |
|
8 Therapeutic implications of anti-inflammatory natural products in Alzheimer's disease |
|
|
241 | (18) |
|
|
Muhammed Khairujjaman Mazumder |
|
|
|
|
|
|
|
|
241 | (1) |
|
2 Neuroinflammation in Alzheimer's disease |
|
|
242 | (1) |
|
3 Implementation of anti-inflammatory natural products in Alzheimer's disease |
|
|
243 | (7) |
|
|
243 | (2) |
|
|
245 | (1) |
|
|
245 | (1) |
|
|
246 | (1) |
|
|
246 | (1) |
|
|
247 | (1) |
|
3.7 Epigallocatechin-3-gallate |
|
|
247 | (1) |
|
|
248 | (1) |
|
|
248 | (1) |
|
|
248 | (1) |
|
|
249 | (1) |
|
|
249 | (1) |
|
|
250 | (1) |
|
|
250 | (1) |
|
|
251 | (1) |
|
|
252 | (7) |
|
9 Anti-inflammatory effects of probiotics |
|
|
259 | (24) |
|
|
|
|
259 | (1) |
|
|
260 | (1) |
|
|
260 | (5) |
|
|
261 | (1) |
|
3.2 Genus Bifidobacterium |
|
|
262 | (1) |
|
|
263 | (1) |
|
|
263 | (2) |
|
|
265 | (4) |
|
4.1 Cell-to-cell interaction |
|
|
266 | (1) |
|
4.2 Antimicrobial activity |
|
|
267 | (1) |
|
4.3 Immunomodulatory activity |
|
|
268 | (1) |
|
5 Therapeutic use of probiotics |
|
|
269 | (5) |
|
5.1 Gastrointestinal diseases |
|
|
269 | (2) |
|
|
271 | (2) |
|
5.3 Allergies and dermatitis |
|
|
273 | (1) |
|
|
273 | (1) |
|
|
274 | (1) |
|
|
275 | (1) |
|
|
275 | (7) |
|
|
282 | (1) |
|
10 6-Gingerol: a therapeutically potent lead candidate in anti-inflammatory drug discovery |
|
|
283 | (14) |
|
|
|
283 | (1) |
|
2 Biosynthesis of 6-gingerol |
|
|
283 | (3) |
|
3 Anti-inflammatory potential of 6-gingerol |
|
|
286 | (4) |
|
4 Pharmacokinetics of 6-gingerol |
|
|
290 | (1) |
|
|
291 | (1) |
|
|
291 | (1) |
|
|
291 | (6) |
Index |
|
297 | |